

Driving digitalization at scale in the lab

Fuel productivity and collaboration for faster innovation

The biopharma industry responded to the pandemic with new urgency, delivering life-saving vaccines at unprecedented speed. These breakthroughs have reset expectations for the discovery, development and delivery of new treatments.

Already in innovation mode, R&D organizations and their scientific labs are looking to expand digital capabilities and further transform productivity.

Progress in digital lab transformation continues across organizations, accelerated by the pandemic. The need to support New Science¹, collaborate internally and externally, and accelerate time to file are key drivers behind this progress. Research, development, and QC manufacturing labs are unique and more than technology is required to speed transformation.

1. New Science includes a spectrum of treatments that solve for a clear, unmet need through a new mechanism, modality or health technology, such as new cell therapies and curative gene therapies, and often require a new technology device or diagnostics for their development or as a companion to treatment, or could describe the technology alone.

Accenture surveyed 118 industry leaders from scientific labs to better understand how biopharma companies are embracing digital transformation within labs.


Labs² accelerated digitalization efforts in response to COVID-19



2. Scientific labs refer to research, development, and quality control manufacturing labs (QC-M).


Rallying around digital can power key business objectives

Across all labs, core business drivers for advancing digital are:




Percentages represent the averages of responses that selected the item; aggregate of responses across all lab types – research, development, and QC manufacturing labs.

No matter the type of lab, New Science is a key driver for digitalization




Percentages represent responses per respective lab type that selected New Science as a business driver for digitalization.


Those who have scaled up digitalization report significant value




Progress is creating momentum for more adoption



People play a vital role in accelerating digital transformation



Fuel and accelerate digital lab transformation



About Accenture
Accenture is a global professional services company with leading capabilities in digital, cloud and security. Combining unmatched experience and specialized skills across more than 40 industries, we offer Strategy and Consulting, Interactive, Technology and Operations services—all powered by the world's largest network of Advanced Technology and Intelligent Operations centers. Our 699,000 people deliver on the promise of technology and human ingenuity every day, serving clients in more than 120 countries. We embrace the power of change to create value and shared success for our clients, people, shareholders, partners and communities. Visit us at www.accenture.com.

About the research
Accenture surveyed 118 leaders in the life sciences industry to understand how biopharma companies are using new technologies within the discovery, research, development and quality control stages of the drug product lifecycle. Respondents worked for pharma companies (51%), biotech companies (46%), medical device manufacturers (2%) and large service providers (2%). All respondents were in the United States (69%) and Europe (31%), at levels of director or higher (76%), with 59% in either executive management or R&D management. The survey was conducted in March 2021.

© Copyright 2022 Accenture. All rights reserved. Accenture and its logo are trademarks of Accenture.
This content is provided for general information and is not intended to be used in place of consultation with our professional advisors.